News from ODYSSEY OUTCOMES: Effects of PCSK9 inhibition on total cardiovascular disease burden New US Cholesterol Guidelines: The good, the bad and the ugly ODYSSEY ALTERNATIVE follow-up: Sustained LDL lowering in statin-intolerant patients No adverse effects of very low LDL cholesterol on cognition: further data from FOURIER EVOLVD trial in heart transplant recipients PCSK9 inhibition, low LDL cholesterol and lack of cognitive impairment: QED?ODYSSEY OUTCOMES Economics Study: How can we get the best value from PCSK9 inhibitors?Alirocumab safe in patients with diabetes mellitus

About the PCSK9 Education and Research Forum

PCSK9 Education and Research Forum is the independent resource on PCSK9 science and its translation into critically important new treatments to lower low density lipoprotein cholesterol (LDL-C), which promise to transform the prognosis of millions of patients with hypercholesterolaemia (cholesterol disorders), accelerated atherosclerotic vascular heart disease and a high risk of premature cardiovascular (CV) death and disability.
Aims & Objectives Mission Statement Editorial Board Partnership & Outreach Forthcoming Meetings

Download Now: New Slide Deck Programme

Previous slide decks focused on landmark studies which used a monoclonal antibody approach to inhibit PCSK9. The next in this series discusses inclisiran, a small interfering RNA therapy, which prevents production of PCSK9 at its primary source in the liver.

Find out more »

Download NowUNIQUE FREE APPAdvances in lipid lowering - a clinical guide

ACC.20 with the World Congress of Cardiology

Virtual Meeting 28-30 March

Polygenic risk, LDL and SBP
Inclisiran: Data for >3,600 patients
Evinacumab: Nearly halves LDL-C in HoFH
ODYSSEY HoFH: Alirocumab shows benefit

AHA Scientific Sessions 2019

16-18 November, Philadelphia, USA

ORION-9: durable and potent LDL-C lowering in HeFH patients on twice yearly dosing
FOURIER: effects of evolocumab on cognition and following MI

Most viewed

EVOLVD trial in heart transplant recipients Pooled analyses confirm benefit of PCSK9 inhibitors on secondary lipid targets PCSK9 inhibition, low LDL cholesterol and lack of cognitive impairment: QED? No adverse effects of very low LDL cholesterol on cognition: further data from FOURIER ODYSSEY OUTCOMES economics study reinforces highest risk-highest benefit premise ODYSSEY ALTERNATIVE follow-up: Sustained LDL lowering in statin-intolerant patients Are very low LDL-C levels on a PCSK9 inhibitor safe? PCSK9 inhibition and neurocognitive effects:Weighing up the evidence Low LDL-C and cognitive function: Benefit or harm? VIDEO: Prof Greg Schwartz Candidates for PCSK9 inhibition

Most viewed

EVOLVD trial in heart transplant recipients

Hot Topics

ODYSSEY OUTCOMES: impact on hospitalisation

Prof. Anthony Wierzbicki, Guy's & St Thomas' Hospitals, London, UK discusses this analysis evaluating the impact of PCSK9 inhibition on hospitalisation following ACS

Read the report
Other related reports:
AHA 2018 ODYSSEY OUTCOMES Total Events Analysis
View the video
PCSK9 inhibitors: How do we weigh up the benefit versus cost of treatment?
View the video
FOURIER: Evolocumab reduced the burden of total cardiovascular events
Read the report

From the Editors

PCSK9 inhibition, low LDL cholesterol and lack of cognitive impairment: QED?

Prof Derick Raal, University of the Witwatersrand, Johannesburg, South Africa, discusses the latest data from FOURIER regarding cognitive safety. What is the take home message for clinicians?

Read the report

Other related reports:
Low LDL-C and cognitive function: Benefit or harm?
Watch the webcast
Do the PCSK9 monoclonal antibodies have neurocognitive effects
Watch the video
PCSK9 inhibition and neurocognitive effects:Weighing up the evidence
Read the report